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Abstract: The incidence of early onset colorectal cancer (EOCRC) is rapidly increasing, but there 
remains paucity of outcome data for young CRC patients. We reviewed the characteristics and 
outcomes of 241 adults, age <50, who were diagnosed with EOCRC between January 2009 and 
December 2014. Median age was 42, 56% were male, and 7% had hereditary etiology. Seventy 
percent had left-sided primaries. At diagnosis, 11%, 50%, and 39% had stage II, III, and IV CRC. Of 
the patients with stage II and III CRC who underwent curative surgery, 60% and 88% had adjuvant 
chemotherapy, with 5-year relapse free survival of 82% and 74% respectively. Of the 123 patients 
with metastatic (m) EOCRC, 93%, 63%, 33%, and 12% had 1st, 2nd, 3rd, and 4th line systemic 
anticancer therapy (SACT) respectively. For first line SACT, 99% had doublet chemotherapy, with 
bevacizumab or an anti-EGFR antibody in 57%. Median overall survival (mOS) of mEOCRC patients 
was 20.1 months (95% C.I: 15.9–23.2). Younger age and signet cells were associated with shorter 
mOS, whereas more lines of SACT and curative metastasectomy with longer mOS. Metastatic 
EOCRC patients had poorer outcomes than expected, despite optimal multimodality treatment. 
This suggests an aggressive disease biology that warrants further research and therapy 
development. 
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1. Introduction 
Colorectal cancer (CRC) is the third most common cancer diagnosis worldwide [1]. It is 
traditionally considered a disease of older adults, therefore, in the United Kingdom (UK) fecal occult 
blood CRC screening is typically reserved for people over the age of 60. Similarly, CRC screening is 
limited to patients older than 50 years in the United States of America (USA) [2]. Early onset colorectal 
cancer (EOCRC) is defined as diagnosis of CRC in patients younger than 50 years old. Over recent 
years, there has been a significant increase in the incidence of EOCRC, with the highest rate of 
increase seen in rectal cancer. Epidemiological studies across the globe, including in Europe, Canada, 
USA, Australia, China, India, Japan, and Brazil, report a similar rise in incidence of CRC in young 
adults over the last 20–25 years [3–6]. In the USA, colon cancer incidence rates increased by 1.0% to 
2.4% annually since the mid-1980s in adults age 20 to 39 years and by 0.5% to 1.3% since the mid-
Cancers 2019, 11, 1558 2 of 16 
 
1990s in adults aged 40 to 54 years. Rectal cancer incidence rates have been increasing for longer and 
more rapidly (3.2% annually from 1974 to 2013 in adults aged 20–29 years) [7]. It is estimated that 
around 11% of colon cancers and 18% of rectal cancers occur in individuals younger than 50 years of 
age [8]. 
EOCRC appears to be a heterogeneous disease with distinct clinicopathological and molecular 
characteristics. Young adults tend to have a higher prevalence of low-grade tumor differentiation, 
mucinous and signet ring cell tumors when compared to older patients [9,10]. A proportion of 
EOCRC can be attributed to hereditary syndromes. It is estimated that up to 20–30% of EOCRC has 
a hereditary component. Of these, only 3–5% have a well-characterized genetic basis [11]. The rate of 
EOCRC attributed to known hereditary syndromes is heavily influenced by the age groups analyzed, 
with patients <35 years old exhibiting the highest rates [12]. Lynch Syndrome (LS) is the most 
prevalent hereditary syndrome, followed by familial adenomatous polyposis (FAP), Peutz–Jeghers 
syndrome, juvenile polyposis syndrome, and others. The reported prevalence of LS in EOCRC 
cohorts is variable ranging from 4% to 20% [13]. The underlying pathogenesis of LS relates to the 
presence of germ-line mutations in one of the DNA mismatch repair (MMR) genes, which in itself 
results in microsatellite instability (MSI) [14]. In addition to MSI secondary to LS, MSI tumors can 
also be found in sporadic, nonhereditary cases. The majority of these cases occur secondary to 
epigenetic silencing of the MLH1 gene. Overall it is estimated that 15% to 20% of cases of EOCRC 
have MSI, a rate that is higher than that of older adults, albeit still a minority group [15]. 
The current literature relating to EOCRC is mainly limited to epidemiological studies that 
characterized the incidence and prognosis of younger adults with CRC. There is currently very sparse 
literature describing treatment pathways of these patients and their associated outcomes. 
We aimed to profile the clinicopathological characteristics and treatment outcomes of patients 
with EOCRC (age <50 years) in the real-world setting of a single high-volume tertiary UK cancer 
center. 
2. Results 
2.1. Patient Characteristics 
During the 6-year period of 1 January, 2009 to 31 December, 2014, a total of 561 patients aged 
18–49 were registered at Royal Marsden Hospital (RMH) and had a diagnosis of CRC. Out of the 561 
patients, 241 (43%) patients met our inclusion criteria. The excluded patients had received their 
treatment in other UK centers or overseas and therefore their treatment outcomes were not available 
for extraction. The majority of excluded patients attended RMH for a single specialist review with 
the surgical, clinical, or medical oncology teams, including consultations to discuss participation in 
clinical trials. 
The median age of all included patients was 42 years old (range 19 to 49) and 56% were male 
(Table 1). In total, 103 (43%) patients were <40 years old. The majority of patients declared a white 
British (65%) ethnicity followed by Asian or Asian British (10%). The Body Mass Index (BMI) within 
3 months of diagnosis was available for 227 (94%) patients. The median BMI was 24.9 kg/m2 (95% C.I 
24.3–25.2), with a mean of 25.1 kg/m2 (range 16.4–40.9). Overall, 231 (96%) patients had an Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) of 0 or one at diagnosis. 
Twenty-seven (11%) patients presented with stage II disease. Most patients presented with stage 
III disease (n = 120, (50%)) and 93 (39%) patients had metastatic disease at diagnosis. 
Overall the majority of patients had a left sided primary tumor (70%) with rectum/rectosigmoid 
being the most prevalent primary site (n = 102 (43%)) followed by descending or sigmoid colon (n = 
64 (27%)) and caecum/ascending colon (n = 57 (24%)). 
There were 23 cases (10%) of mucinous adenocarcinoma. Six (2%) patients had signet cells and 
out of these, five (83%) had metastatic disease at diagnosis. Most primary tumors (73%) were 
moderately differentiated, whereas 19% were poorly differentiated. 
MMR status, assessed by immunohistochemistry, was available in 165 (68%) patients, and of 
these, 148 (90%) had MMR proficient tumors. In patients with known MMR status with stage II 
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disease at diagnosis, 12% had MMR deficient tumors. In patients with stage III disease the rate of 
MMR deficiency was 16%, whereas in patients with stage IV disease at diagnosis, only one (2%) 
patient had MMR deficient CRC. Out of the 17 patients that were known to have MMR deficient 
tumors, 11 (65%) patients were known to have Lynch syndrome. 
A total of sixteen patients (7%) with EOCRC were found to have a known hereditary syndrome. 
As expected, the most prevalent hereditary syndrome was Lynch syndrome (n = 11). 
Routine molecular characterization of patients’ tumors with stage IV disease evolved during the 
course of the 6-year period included (January 2009–December 2014). In 2009, molecular 
characterization was not part of patients’ routine care. Subsequently, KRAS mutation testing was 
carried out and by 2014, exon 2–4 NRAS/KRAS and BRAF mutation testing was considered standard 
of care. As a result of this, the majority of the included patients have an unknown NRAS and BRAF 
genetic mutation status. Out of the 134 patients with known KRAS status, 37% had a known activating 
mutation. 
Table 1. Baseline patient demographics and disease characteristics by stage at diagnosis. ECOG, 
Eastern Cooperative Oncology Group. 
Variable Stage II  
n (%) 
Stage III  
n (%) 
Stage IV  
n (%) 
All Patients  
n (%) 
Stage at diagnosis * 27 (11) 120 (50) 93 (39) 241 (100) 
Sex     
Female 13 (48)  47 (39) 46 (49) 107 (44) 
Male 14 (52) 73 (61) 47 (51) 134 (56) 
Age     
Mean 40 40 41 40 
Median 40 43 43 42 
Range (min–max) 25–49 25–49 21–49 19–49 
<20 0 (0) 1 (<1) 0 (0) 1 (<1) 
20–29 2 (7) 12 (10) 10 (11) 24 (10) 
30–39 11 (41) 39 (33) 28 (30) 78 (32) 
40–49 14 (52) 68 (57) 55 (59) 138 (57) 
Ethnic Background     
White British 14 (52) 77 (64) 64 (69) 156 (65) 
White Irish 0 (0) 3 (2) 1 (1) 4 (2) 
White Other 2 (7) 8 (7) 8 (9) 18 (7) 
Asian/Asian-British 2 (7) 14 (12) 8 (9) 24 (10) 
African/Caribbean/Black British 4 (15) 10 (8) 4 (4) 18 (7) 
Mixed/Multiple (Other Mixed) 1 (4) 0 (0) 0 (0) 1 (<1) 
Another Ethnic Group 4 (15) 8 (7) 8 (9) 20 (8) 
ECOG PS      
0 12 (44) 24 (20) 16 (17) 52 (22) 
1 15 (56) 95 (79) 68 (73) 179 (74) 
2 0 (0) 1 (1) 4 (4) 5 (2) 
3 0 (0) 0 (0) 5 (5) 5 (2) 
Location of primary tumor     
Caecum/ascending colon 5 (18) 31 (26) 21 (23) 57 (24) 
Transverse colon 3 (11) 10 (8) 5 (5) 18 (7) 
Descending colon/sigmoid 7 (26) 26 (22) 31 (33) 64 (26) 
Recto-sigmoid 1 (4) 4 (3) 11 (12) 16 (7) 
Rectum 11 (41) 49 (41) 25 (27) 86 (36) 
Histology     
Adenocarcinoma 23 (85) 103 (86) 83 (89) 210 (87) 
Mucinous adenocarcinoma 4 (15) 16 (13) 3 (3) 23 (10) 
Signet cell 0 (0) 1 (1) 5 (5) 6 (2) 
Unknown 0 (0) 0 (0) 2 (2) 2 (1) 
Primary Tumor differentiation     
Well 1 (4) 3 (2) 0 (0) 4 (2) 
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Moderate 23 (85) 93 (78) 60 (65) 176 (73) 
Poor 3 (11) 21 (18) 20 (21) 45 (19) 
Unknown 0 (0) 3 (2) 13 (14) 16 (6) 
KRAS     
Mutant 8 (30) 18 (15) 23 (25) 49 (20) 
Wild type 4 (15) 35 (29) 46 (50) 85 (35) 
Unknown 15 (55) 67 (56) 24 (26) 107 (44) 
NRAS     
Mutant 0 0 0 0 
Wild type 6 (22) 31 (26) 28 (30) 65 (27) 
Unknown 21 (78) 89 (74) 65 (70) 176 (73) 
BRAF     
Mutant 0 (0) 8 (7) 4 (4) 12 (5) 
Wild type 6 (22) 24 (20) 24 (26) 54 (22) 
Unknown 21 (78) 88 (73) 65 (70) 175 (73) 
MMR     
Deficient 3 (11) 13 (11) 1 (1) 17 (7) 
Proficient 22 (82) 69 (57) 56 (60) 148 (61) 
Unknown 2 (7) 38 (32) 36 (39) 76 (32) 
Hereditary Syndromes      
Lynch syndrome 3 (11) 7 (6) 1 (1) 11 (5) 
FAP 1 (4) 0 (0) 0 (0) 1 (<1) 
Other 0 (0) 3 (3) 1 (1) 4 (2) 
* 1 patient had stage I rectal cancer at diagnosis. 
2.2. Treatment and Outcomes in Patients with Stage II and III EOCRC 
2.2.1. Neo-Adjuvant Chemoradiation 
A total of 48 (80%) patients with stage II or III rectal cancer were treated with neo-adjuvant 
radiotherapy and out of these patients, 44 (92%) received long course chemo-radiation with 
concomitant capecitabine or 5FU. On pretreatment MRI imaging, a total of 23 (48%) patients had 
documented circumferential resection margin involvement (CRM) and 32 (67%) patients had 
evidence of extramural vascular invasion (EMVI). A total of four (8%) patients had evidence of local 
or systemic relapse after completion of radiotherapy (+/− chemotherapy). 
2.2.2. Curative Surgery and Adjuvant Chemotherapy 
A total of 15 (60%) out of 25 patients with stage II disease that had a documented history of 
curative surgery went on to have adjuvant chemotherapy. Of these patients 80% had adjuvant 
capecitabine or 5FU alone. The 5-year relapse-free survival (RFS) for stage II patients was 82.2% 
(Figure 1). 
Out of the 109 patients with stage III disease that had curative surgery, 96 (88%) patients were 
treated with adjuvant chemotherapy. Out of the patients that received adjuvant chemotherapy, 86% 
patients had standard of care oxaliplatin-based doublet chemotherapy, while four patients had 
oxaliplatin-based doublet in combination with targeted therapies within clinical trials. The 5-year 
relapse-free survival (RFS) for stage III patients was 74.1% (Figure 1). 
Out of all the patients that were treated with adjuvant chemotherapy, 13 (12%) patients had 
discontinuation of their adjuvant chemotherapy earlier than planned, while 30% required a treatment 
delay during the 6-month course of their adjuvant chemotherapy. Moreover, in 34 of the 88 (39%) 
patients that were treated with oxaliplatin-based doublet chemotherapy, oxaliplatin was 
discontinued early, during their 6-month course of treatment. 
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Figure 1. Adjuvant chemotherapy and Relapse Free Survival in patients with stage II and II colorectal 
cancer (CRC). (a) Adjuvant chemotherapy regimens in 15 patients with stage II CRC; (b) Adjuvant 
chemotherapy regimens in 96 patients with stage III CRC; (c) Kaplan–Meier estimates for relapse-free 
survival (RFS) in all patients with Stage II and III disease. 5FU: 12 cycles, each 14-day cycle; 5FU bolus 
400 mg/m2, 5FU 2400 mg/m2 infusion over 48 h and folinic acid 350 mg. Capecitabine 8 cycles each 21-
day cycle; capecitabine 2000 mg/m2 per day in two divided doses for 14 days followed by 7-day rest. 
CAPOX: 8 cycles, each 21-day cycle; capecitabine 1700 mg/m2 per day in two divided doses for 14 days 
followed by 7-day rest and oxaliplatin 130 mg/m2 on day 1. FOLFOX: 12 cycles, each 14-day cycle; 
5FU bolus 400 mg/m2, 5FU 2400 mg/m2 infusion over 48, folinic acid 350 mg and oxaliplatin 85 mg/m2 
on day 1. Other: experimental combinations that were administered only within clinical trials: 
experimental regimens were FOLFOX or CAPOX with targeted therapies. 
2.3. Treatment and Outcomes in Patients with Stage IV EOCRC 
A total of 123 patients with mEOCRC were included. Out of these, 93 (76%) patients had stage 
IV disease at diagnosis, while two (2%) patients had stage II and 28 (23%) had stage III disease at 
diagnosis and relapsed with metastatic disease subsequently. A total of 114 (93%) patients were 
treated with SACT for mEOCRC, while the rest of the patients were either of a poor PS at diagnosis 
and did not receive SACT or had oligometastatic disease and were treated with metastasectomy 
alone. 
The most commonly administered regimens per line of SACT are shown in Figure 2. In the first 
line metastatic setting, out of the 114 patients that received SACT, 113 (99%) patients received a 
doublet chemotherapy regimen, with the addition of bevacizumab in 48% of patients. 
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Figure 2. The most frequently used systemic anticancer therapy (SACT) regimens in the metastatic 
setting in (a) first line, (b) second line, (c) third line, and (d) fourth line setting. Epidermal Growth 
Factor Receptor (EGFR) Monoclonal antibody (MoAb) therapy (cetuximab 500 mg/m2 2-weekly or 
panitumumab 6 mg/kg 2-weekly) was only offered in patients with known KRAS wild type tumors. 
FOLFIRI (14 day cycle: 5FU bolus 400 mg/m2 and 5FU 2400 mg/m2 infusion over 48 h, folinic acid 350 
mg and irinotecan 180 mg/m2 day 1), CAPIRI (21 day cycle: capecitabine 1700 mg/m2 per day in two 
divided doses for 14 days followed by 7 day rest and irinotecan 200 mg/m2 on day 1), FOLFOX (14 
day cycle: 5FU bolus 400 mg/m2,5FU 2400 mg/m2 infusion over 48 h folinic acid 350 mg and oxaliplatin 
85 mg/m2 on day 1), CAPOX (21 day cycle: capecitabine 1700 mg/m2 per day in two divided doses for 
14 days followed by 7 day rest and oxaliplatin 130 mg/m2 on day 1). Bevacizumab in all 3-weekly 
regimens at 7.5 mg/kg, 2 weekly regimens at 5 mg/kg. Aflibercept at 4 mg/kg 2 weekly. Regorafenib 
4 weekly cycles at 160 mg once a day (OD) for 21 days followed by 7-day rest. 
The documented partial response (PR) stable disease (SD) and progressive disease (PD) rates in 
the first line setting regardless of regimen were 40%, 23%, and 32% respectively. The median PFS in 
the first line setting, was 6.9 (95% C.I: 5.8–9.4) months (Table 2). 
Of the patients that had first line SACT, 78 (68%) went on to have a 2nd line SACT. The most 
commonly used regimen in the second line setting was irinotecan-based combination with or without 
the addition of bevacizumab (36% and 19% respectively). The documented PR, SD, and PD rates were 
17%, 26%, and 51% respectively. The median progression-free survival (PFS), irrespective of regimen, 
in the second line setting was 5.0 (95% C.I: 3.4–6.1) months (Table 2). 
A total of 33%, 12%, and 5% of all patients with mEOCRC went on to receive 3rd, 4th, and 5th 
line treatments respectively. The most commonly utilized SACT regimens in the 3rd and 4th line 
setting are shown in Figure 2 and outcomes per line of therapy in Table 2. As the number of lines of 
SACT increased, so did the participation of treatment within a clinical trial setting, with 20% of 
patients treated within clinical trials from the third line setting onwards. 
The median overall survival (mOS) increased with increasing number of sequential lines of 
SACT (Table 2). Patients that were only able to receive a total of one line of SACT had a mOS of 9.0 
(95% C.I: 4.1–27.7) months. Patients that received a total of two lines had a mOS of 14.9 (95% C.I: 9.6–
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19.0) months, while those that had a total of three and four lines of SACT had a mOS of 18.7 (95% C.I: 
14.3–28.6) and 31.7 (95% C.I: 20.2–46.5) months respectively. 
Table 2. Patient outcomes by total number of SACT received in the metastatic setting. 
Line of Metastatic SACT  1st  2nd  3rd  4th 5th 
Number of Patients 114 78 40 15 6 
Best response for each line of SACT n (%) 
CR 4 (3) CR 1 (1) CR 0 (0) CR 0 (0) CR 0 (0) 
PR 46 (40) PR 13 (17) PR 3 (8) PR 1 (7) PR 0 (0) 
SD 26 (23)  SD 20 (26) SD 9 (23) SD 2 (13) SD 2 (33) 
PD 36 (32) PD 40 (51) PD 28 (70) PD 11 (73) PD 4 (67) 
NA 2 (2) NA 4 (5) NA 0 (0) NA 1 (7) NA 0 (0) 
Regimen modification n (%) 43 (38) 17 (22) 4 (10) 3(20) 0 
Median PFS for each line of SAC.T (95% CI), months 
6.9 5.0  2.0  3.9  2.7  
(5.8–9.4) (3.4–6.1) (1.7–3.8) (1.7–5.4) (1.5–NA) 
Median OS (95% C.I) for patients whose total lines of 
SACT in metastatic setting was: (months) 
9.0 14.9 18.7  31.7  32.0  
(4.1–27.7) (9.6–19.0) (14.3–28.6) (20.246.5) (N/A) 
Legend: SACT: systemic anticancer therapy, CR: complete response, PR: partial response, SD: stable disease, PD: 
progressive disease, NA: not applicable. PFS: progression-free survival, OS: overall survival. 
A total of 17 (14%) patients underwent metastasectomy with curative intent. In addition, patients 
with metastatic disease received the following palliative treatments during the course of their 
treatment: 27 (22%) patients had palliative radiotherapy, 21 (17%) patients had palliative surgery to 
the primary tumor, 11 (9%) patients had radiofrequency ablation (RFA) to the liver and or lung 
metastases, four (3%) patients had stereotactic radiosurgery, four (3%) patients had selective internal 
radiation therapy (SIRT) to liver metastasis, and two (2%) patients had microwave ablation to the 
liver. 
The mOS for all patients with mEOCRC was 20.1 months (95% C.I: 15.9–23.2). For the 93 patients 
that presented with stage IV disease (n = 93), mOS was 18.8 months (95% C.I: 14.3–22.6). In the case 
of patients that relapsed with systemic metastases following an initial diagnosis of stage II (n = 2) and 
III (n = 28) disease, the mOS from the time of diagnosis of metastatic disease was 9.1 (95% C.I N/A) 
months and 26.2 (95% C.I: 15.7–49.6) months respectively. 
2.4. Prognostic Markers of Survival in Patients with Stage IV CRC 
As expected, the 17 (14%) patients that had curative metastasectomy had a statistically 
significant longer mOS (p < 0.001), when compared to patients that did not (Figure 3). In addition, 11 
(9%) patients that had metastatic disease that was deemed treatable with local ablative therapy to the 
liver and/or lung metastases also had significantly longer mOS (Figure 3). The latter analysis may 
have been confounded by the fact that these patients were likely to have had oligo-metastatic disease. 
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Figure 3. Prognostic markers for overall survival in metastatic disease. Kaplan–Meier estimates of 
overall survival according to (a) whether patients underwent metastasectomy with curative intent, 
(b) whether they had radiofrequency ablation to liver and/or lung metastases, and (c) age at diagnosis, 
≤40 years old or >40 years old. p-values refer to log rank test. 
Patients with signet cells (5%) had a significantly shorter mOS, although this analysis was 
limited by the small number of patients with signet cell histology (Table 3). 
Younger age at presentation was associated with a numerically shorter mOS. As shown in Figure 
3c, patients age ≤40 had mOS of 16.1 (95% C.I 9.9–28.6) compared to 21.7 months in patients age >40 
group (95% C.I 16.2–27.7). 
When considering age groups per decade cohorts there was an inverse relationship between age 
and mOS, with youngest patients having numerically the shortest mOS (p < 0.05): 
• age 20–29 (n = 13), mOS 15.9 (95% C.I 7.0–43.0) 
• age 30–39 (n = 37), mOS 17.1 (95% C.I not reached) 
• age 40–49 (n = 72), mOS 21.7 (95% C.I 16.2–27.7) 
The location of primary tumor (left vs. right sided) and KRAS and BRAF mutation status did not 
significantly impact on mOS (Table 3). The BRAF analysis was limited by the small number of patients 
that had known BRAF genotyping results, although, as expected, patients with BRAF wild type 
tumors had a numerically longer mOS when compared to patients with BRAF mutant tumors (Table 
3).  
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Table 3. Prognostic variables for overall survival in the metastatic setting. mOS, Median 
overall survival 
Prognostic Variable 
Number of 
Patients 
mOS  
(95% C.I) Months p-Value 
Histopathology    
Adenocarcinoma 107 20.2 (16.1–26.7) 
p < 0.001 Mucinous Adenocarcinoma 7 15.8 (NA) 
Signet cells 5 7.0 (NA) 
Location of Primary      
Left 90 22.5 (16.2–27.7) 
p = 0.18 
Right 33 15.9 (9.0–22.0) 
KRAS Status *    
Mutant 32 18.5 (11.7–26.2) p = 0.38 
Wild Type 56 22.6 (17.1–28.8) 
BRAF Status **    
Mutant 7 17.1 (NA) 
p = 0.45 Wild Type 34 23.2 (16.0–46.5) 
Legend: p-value refers to log rank test; * In 35 patient KRAS status was unknown; ** In 82 patients 
BRAF status was unknown. 
3. Discussion 
It is now recognized that the incidence of EOCRC is increasing rapidly at a global scale [3–6]. In 
the USA it is predicted that based on current trends, in 2030, the incidence rates for colon and rectal 
cancers will increase by 90.0% and 124.2%, respectively, for patients aged 20 to 34 years and by 27.7% 
and 46.0%, respectively, for patients aged 35 to 49 years [16]. 
In our study, a total of 561 patients, age <50, with EOCRC were registered over the 6-year period 
from January 2009 to December 2014. The sheer number of patients with EOCRC that were registered 
at a single cancer center, further highlights that patients with EOCRC represent a sizeable group, who 
merit further consideration in terms of bespoke therapy development and configuration of services. 
Out of the of 241 (43%) patients that met our inclusion criteria, 56% were male and the majority 
(65%) declared a White British ethnic background, followed by 10% that declared Asian/Asian-British 
background. Overall, the ethnic background data of our population, while reflective of the multi-
cultural London population, also suggest that in the UK, EOCRC is likely to span all ethnic 
backgrounds. Studies to date sought to identify population subgroups with the highest 
predisposition to EOCRC. While there have been some discrepancies between the outcomes reported 
in different countries, overall, the increase in incidence rates of EOCRC appears similar between 
males and females [5]. In the USA, there is data to suggest that there are persistent disparities by 
race/ethnicity and possibly socio-economic status. However, these disparities may reflect the relative 
distribution of other risk factors that are known to be associated with CRC, such as obesity and type 
II diabetes in these subgroups [17–19]. Our cohort had a median BMI that was within the normal 
distribution, median of 24.9 kg/m2, albeit at the uppermost limit of normality. 
In our population there was a left sidedness preponderance with 43% of patients having rectal 
or recto-sigmoid tumors as their primary site. Only 21% of patients presented with stage I or II 
disease, while 39% of patients had metastatic disease at diagnosis. Overall, our findings are in line 
with other studies that suggest that the incidence of rectal cancer is increasing most rapidly in young 
adults and that these patients tend to be diagnosed with advanced disease stage [19–22]. It is however 
worth noting that other epidemiological data from Europe suggests that the largest increase in CRC 
incidence in young adults is in fact of colon rather than rectal origin [3,23], thereby, challenging recent 
suggestions of screening strategies in young adults with flexible sigmoidoscopy alone [24]. 
Although we have not been able to investigate the prior diagnostic pathway of our patients, it 
has been previously suggested that young patients with CRC report symptoms for a longer period of 
time, prior to diagnosis, than their older counterparts [25,26]. It is possible that young CRC patients 
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present with symptoms, such as bleeding per rectum, that are initially attributed to benign causes 
such as hemorrhoids, which may co-exist. On the other hand, young adults are more likely to have 
competing responsibilities and may be less likely to seek professional help early, as they may 
normalize or wrongly attribute their symptoms to something other than cancer, thereby further 
adding to potential diagnostic delay [27]. Globally, established CRC screening programs in their 
current shape include patients >50 years old and although there is no data to confirm this, it is possible 
that this may contribute to the fact that young patients tend to present with more advanced stage at 
diagnosis. Our data adds further evidence supporting recent publications that suggest that CRC 
screening should be more inclusive of younger patients [28]. Indeed, the American cancer society has 
recently recommended lowering the age to start CRC screening from 50 to 45 years with either a high-
sensitivity stool-based test or a structural (visual) examination, depending on patient preference and 
test availability [29]. 
In our cohort a minority of patients had a known hereditary syndrome (7%), with the most 
prevalent syndrome being, as expected, Lynch syndrome. Overall the rate of known hereditary 
syndromes in our cohort is at the lower end of the spectrum when compared to previously reported 
studies [12,13]. This may have been due to the fact that other retrospective studies in EOCRC included 
a younger group by only including patients aged <40 years old. It is well established that the younger 
the median age of the EOCRC cohort, the higher the rate of hereditary etiology [12,19]. Patients with 
known hereditary syndromes remain an important proportion of the EOCRC population that require 
specialist cancer genetics input and specialized surveillance strategies. Nevertheless, it is also 
important to acknowledge that the majority of young adults with CRC are in fact patients with 
nonhereditary sporadic tumors. 
Our molecular characterization results for MMR status as well as KRAS/NRAS and BRAF 
mutation rates reflect the fact that during the earlier years of data collection, molecular 
characterization was not routinely carried out, which is currently not the case. Our data is in line with 
the existing literature on rates of KRAS mutations in the general CRC population and also with that 
reported in other retrospective EOCRC series [30,31]. Our MMR deficiency rates are consistent with 
that reported by other studies that also suggested that MSI tumors are more common in EOCRC 
[15,31]. In line with the general CRC population, our EOCRC patients with MMR deficient tumors 
had an earlier stage at diagnosis when compared to patients with MMR proficient tumors. Only one 
in 17 (6%) patients with MMR deficient CRC presented with metastatic disease, as compared to our 
overall 39% rate of metastatic CRC at diagnosis. This is of clinical relevance, as patients with MMR 
deficient tumors are likely to respond to immune checkpoint inhibitors [32]. 
Importantly, to date, there are no prospective trials that were designed to explicitly investigate 
the efficacy of SACT in young CRC adults. As a consequence of this, the treatment of these patients 
is largely based on extrapolating results from clinical trials that enrolled older patients. We therefore 
sought to analyze the treatment patterns and outcomes of patients with EOCRC, who were treated 
within our UK specialist cancer center, as this would serve as a baseline for future prospective 
research. 
In our patients with stage II disease, a higher than expected proportion (60%) went on to receive 
adjuvant chemotherapy. Clinical trials in age-unselected populations suggested that the absolute 
survival benefit of adjuvant chemotherapy in stage II CRC is in the order of 4% [33]. We speculate 
that the high uptake of adjuvant chemotherapy in our stage II EOCRC patients probably reflects the 
fact that younger patients are willing to have any treatment with possible benefit, even if the 
likelihood of benefit is low. Overall, the RFS rates for both stage II and III patients are comparable to 
that of historical clinical trial controls that enrolled all age groups [34]. It remains unknown as to 
whether intensification of adjuvant chemotherapy in EOCRC is of any benefit. Other retrospective 
trials also suggest that adults with EOCRC receive significantly more postoperative SACT at all 
stages, but they experience only minimal gain in adjusted survival compared with their older 
counterparts who receive less treatment [21,35]. A circulating tumor DNA (ctDNA)-based risk 
stratification strategy may permit for the better selection of patients that are likely to benefit from 
adjuvant chemotherapy and prospective trials investigating this are currently underway [36]. 
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To our knowledge we are the first to profile the regimens used and outcomes per line of 
palliative SACT in young adults with mCRC. In the first line setting, 99% of our patients had doublet 
chemotherapy, with the addition of targeted therapy in more than half of the patients. The majority 
of patients went on to have standard of care second line SACT with a third of all metastatic patients 
having at least three lines of therapy. From the third line SACT setting onwards, 20% of patients had 
their treatment within clinical trials, while the remaining patients often had a rechallenge of 
previously used regimens. Many patients had other additional palliative treatments such as surgery, 
radiotherapy, and localized treatments such as RFA to the liver and/or lung metastases. These results 
are overall reflective of a fit and motivated cohort of patients, who were treated with all evidence-
based multimodality therapies. Whilst noting the limitations associated with a single center (albeit a 
high-volume cancer specialist hospital) our data suggests that there may be scope for prospective 
clinical trials tailored specifically for young adults with CRC. 
The partial response rate and median PFS rates in the first- and second-line metastatic setting 
compare unfavorably to published data in unselected patients in terms of age, including data from 
other real-world observational trials [30,37–39]. In our study, young patients that were able to have 
sequential SACT for metastatic disease had a numerically higher mOS, with a stepwise improvement 
in their mOS with increasing lines of SACT. It is however worth noting that during the data collection 
period included (January 2009–December 2014), first line triplet cytotoxic chemotherapy combination 
with FOLFOXIRI (a combination of 5FU, oxaliplatin, and Irinotecan) and bevacizumab was not 
considered a standard of care option, and therefore it was not one of the used regimens in our study 
[40]. Since 2014, there has been data in support of this regimen and we expect that it is now more 
commonly used in fit young adults with metastatic CRC, especially where a conversion approach is 
possible or in patients with known right sided or BRAF mutant primary tumors [41,42]. 
In the current literature there is scarcity of studies that reported the response to specific SACT. 
We could not identify any other trials that reported PFS and response rates (RR) per line of SACT in 
young patients with mCRC. An older trial, with a pooled analysis of patients from nine first line 
phase III chemotherapy trials using fluorouracil-based single-agent and combination chemotherapy, 
suggested that young age is modestly associated with poorer PFS but not OS or RR in treated patients 
with advanced CRC [43]. The only other trial that reported PFS rates in the first line SACT setting for 
young adults with mCRC by retrospectively assessing the effect of age on outcomes from 24 first line 
clinical trials, reported that younger and older age are associated with poorer OS and PFS when 
compared to middle-aged patients [44]. 
In our study, the mOS of 20.1 months (95% C.I: 15.9–23.2) for all patients with mEOCRC was 
lower than expected, particularly given the fact that these patients were otherwise of a good PS and 
were treated with what were at the time considered the most efficacious multimodality therapies 
available. One of the most notable findings of our study was the fact that younger age at diagnosis 
was in fact associated with a shorter mOS with an inverse relationship between age and mOS. 
We identified signet cell histological subtype which was present in 5% of patients, as a poor 
prognostic marker for OS in mEOCRC. However, given the small number of patients with signet cell 
histology, this cannot explain the overall short mOS of this cohort or the shorter mOS amongst the 
youngest included patients. Previous retrospective studies compared the prognosis of patients with 
EOCRC to that of older counterparts. A recent review of these trials reported mixed results, with 
some studies indicating a poorer prognosis, whereas others support a comparable or even better 
prognosis in comparison with older patients [35]. In line with our results, there have been previous 
reports suggesting that the younger end of the EOCRC spectrum have inferior survival outcomes 
[31,44]. 
In the current literature there is preliminary evidence to suggest that the pathological and 
molecular characteristics of the tumors of young patients with EOCRC differ from that of older 
patients. In line with our results, signet cell histology is over-represented in young patients [9,11]. It 
is likely that the EOCRC is a heterogeneous cohort in terms of disease biology, with the youngest 
patients being likely to have the most aggressive disease phenotype, as also suggested by our results. 
While EOCRC can develop through MSI or chromosomal instability (CIN) pathways, most EOCRC 
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exhibits MSS phenotypes. Genome-wide hypomethylation is a feature of a subgroup of EOCRC. In 
particular, a subset of EOCRC has hypomethylation of LINE-1 sequences compared to later onset 
CRC. LINE-1 hypomethylation has been associated with adverse clinical behaviors. Other groups 
have also reported an excess of tumors that are both MSS without CIN, also known as Microsatellite 
and Chromosome Stable (MACS) tumors, which tend to be over-represented in poor prognosis left 
sided EOCRC tumors [19,45]. A recent study that investigated the molecular characteristics, 
including classification as per the transcriptomic consensus molecular subtyping (CMS), also 
suggested that EOCRC is a heterogeneous cohort with distinct molecular characteristics. The 
youngest patients, age <30, had distinct signaling aberrations with a lower rate of MAPK pathway 
mutations and a higher rate of CTNNB1 mutations. In patients younger than 40 years, CMS1 was the 
most common subtype, partly reflecting the higher rates of MSI. CMS3 and CMS4 were uncommon, 
whereas CMS2 was relatively stable across age groups [46]. Further research aiming to identify 
distinct molecular phenotypes of EOCRC is required as this may allow for future novel therapeutic 
interventions. 
In addition to their differing needs in terms of anticancer therapies, it is also important to 
acknowledge that young patients with CRC are likely to be faced with other psychosocial concerns 
that are distinctly different to that of older patients. For example, these patients are likely to have 
concerns relating to the possible hereditary component of their disease as well as family planning 
and fertility preservation concerns, which should be addressed proactively during treatment 
planning. Other considerations include the impact of surgery, such as living with a stoma, as well as 
the impact of long-term side-effects of chemotherapy (such as oxaliplatin induced neuropathy) and 
late effect of radiotherapy on their professional and personal lives. Lastly, the psychosocial impact of 
having cancer at a young age in patients that were previously fit, who may have young families of 
their own should not be underestimated and the management of this should be incorporated into 
their routine clinical care. CRC services have traditionally been shaped on the assumption that CRC 
is a disease of older adults. We believe that both clinical services and research should adapt to take 
into account the needs of younger patients with CRC. 
4. Materials and Methods 
In this real-world observational study, we included patients with a histologically confirmed 
diagnosis of CRC between 1 January, 2009 to 31 December, 2014 that were age <50 (range 19–49) at 
the time of diagnosis. Patients were identified through the use of hospital diagnostic coding. All 
included patients received systemic anticancer therapy (SACT) at the Royal Marsden Hospital 
(RMH). Patients that had treatments other than SACT, such as surgery and radiotherapy at other 
institutions were also included, as long as this information was available for extraction from their 
electronic patient records. 
Data were collected by review of the electronic patient medical records. The demographic data, 
treatment, response, and survival outcomes were recorded. Radiologic responses were recorded for 
each treatment line at the first response assessment point, on completion of treatment, and at any 
subsequent progression assessment point. 
All statistical analyses were performed using the STATA 13 software package. The Kaplan–
Meier method was used to estimate PFS and OS and the log-rank test was used to compare survival 
of patient subgroups. A p-value < 0.05 was considered to be statistically significant. 
This study did not require patient consent to participate. A study protocol outlining the 
rationale, methods, and statistical analysis plan was approved by an internal institutional review 
board, the Royal Marsden Hospital’s Committee for Clinical Research, reference number SE474, prior 
to commencement and is available on request. 
5. Conclusions 
Patients with EOCRC that were treated in a single high-volume UK tertiary center had 
predominantly left sided, non-hereditary, primaries with advanced stage at diagnosis. Despite 
treatment with optimal standard of care multimodality therapies, patients with metastatic EOCRC 
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have poorer outcomes than expected. There was an inverse relationship between age and treatment 
outcomes with patients at the younger end of the metastatic EOCRC spectrum exhibiting inferior 
mOS. 
There is data to suggest that EOCRC is increasing rapidly at a global level. EOCRC is likely to 
be a molecularly heterogeneous disease that is distinct to that of older patients. New treatment 
paradigms tailored to target specific EOCRC molecular phenotypes are needed. At the same time 
clinical services should adapt to take the unique psychosocial needs of patients with EOCRC into 
account. 
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